Geovax announces first patients vaccinated in phase 2 clinical trial of covid-19 vaccine booster in patients with chronic lymphocytic leukemia

Atlanta, ga, aug. 10, 2023 (globe newswire) -- seeking improved immune response vs mrna vaccine full patient enrollment expected within six months via newmediawire — geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that vaccinations have begun in an investigator-initiated clinical trial (clinicaltrials.gov identifier:  nct05672355 ) of geo-cm04s1 in patients with chronic lymphocytic leukemia (cll), being conducted at city of hope national medical center. despite a high vaccination rate, cll patients may be at high risk for lethal covid-19 infection due to poor immune response to currently available vaccines.
GOVX Ratings Summary
GOVX Quant Ranking